Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$18.45 - $27.14 $1.74 Million - $2.56 Million
-94,154 Reduced 7.32%
1,192,281 $22.5 Million
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $129,959 - $214,645
6,440 Added 0.5%
1,286,435 $31.7 Million
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $2.97 Million - $6.35 Million
256,670 Added 25.08%
1,279,995 $23 Million
Q2 2022

Aug 11, 2022

BUY
$8.52 - $25.26 $8.72 Million - $25.8 Million
1,023,325 New
1,023,325 $11.6 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.